Adipogen/Empagliflozin/AG-CR1-3619-M010/10 mg
商品编号：
AG-CR1-3619-M010
品牌：
Adipogen Inc
市场价：
¥1400.00
美元价：
840.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | Jardiance; BI-10773; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
| Product Type | Chemical |
| Properties | |
| Formula | C23H27ClO7 |
| MW | 450.9 |
| CAS | 864070-44-0 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White solid. |
| Solubility | Soluble in DMSO. Slightly soluble in water or ethanol. |
| Identity | Determined by 1H-NMR. |
| InChi Key | OBWASQILIWPZMG-QZMOQZSNSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 3 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Antidiabetic agent.
- Potent and selective sodium glucose co-transporter 2 (SGLT-2) inhibitor. >300-fold selectivity over SGLT-1, 4, 5 and 6.
- SGLT-2 is found almost exclusively in the proximal tubules of nephronic components in kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE).
- Shown to preserves β cell mass and restore glucose homeostasis.
Product References
- BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus: I. Aires & J. Calado; Curr. Opin. Investig. Drugs 11, 1182 (2010)
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors: R. Grempler, et al.; Diabetes Obes. Metab. 14, 83 (2012)
- Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats: L. Thomas, et al.; Diabetes Obes. Metab. 14, 94 (2012)
- Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. L. Seman, et al.; Clin. Pharmacol. Drug Dev. 2, 152 (2013)
- The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review: J.B. McGill; Diabetes Ther. 5, 43 (2014) (Review)
- Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes: E.M. Lamos, et al.; Expert Opin. Investig. Drugs 23, 875 (2014) (Review)
- The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat: H.H. Hansen, et al.; J. Pharmacol. Exp. Ther. 350, 657 (2014)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
